Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

Breast

Volumn 15, Issue 2, 2006, Pages 219-225

  Stemmler, H J ^a   Kahlert, S ^a   Siekiera, W ^a   Untch, M ^a   Heinrich, B ^b   Heinemann, V ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Oncological Practice   (Germany)

Author keywords

Brain metastases; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; NAVELBINE; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER GRADING; CANCER REGRESSION; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR LOCALIZATION; VISCERAL METASTASIS;

EID: 33646372698     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.04.017     Document Type: Article

References (28)

1. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
2. Slamon D. Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs 4 Sa (2000) 24-29
3. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., and Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 3 (1996) 737-744
4. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., and Stewart S.J. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61 Suppl 2 (2001) 37-42
5. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., and Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 3 (2002) 719-726
6. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., and Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 9 (1999) 2639-2648
7. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001;37(Suppl 1):S18-24.
8. DiStefano A., Yap H.Y., and Hortobagyi G.N. The natural history of breast cancer patients with brain metastases. Cancer 44 (1979) 1913-1918
9. Tsukada Y., Fouad A., and Pickren J.W. Central nervous system metastases from breast carcinoma: autopsy study. Cancer 52 (1983) 2349-2354
10. Bendell J.C., Domchek S.M., Burstein H.J., Harris L., Younger J., Kuter I., Bunnell C., Rue M., Gelmann R., and Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (2003) 2972-2977
11. Chock J.Y., Domchek S., Burstein H.J., Harris L., Younger J., Kuter I., Rue M., Gelman R.S., and Winer E.P. Central nervous system (CNS) metastases in women who receive trastuzumab for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21 (2002) Abstract
12. Clayton A.J., Danson S., Jolly S., Ryder W.D., Burt P.A., Stewart A.L., Wilkinson P.M., Welch R.S., Magee B., Wilson G., Howell A., and Wardley A.M. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91 4 (2004) 639-643
13. Lai R., Dang C.T., Malkin M.G., and Abrey L.E. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101 (2004) 810-816
14. Lindrud S., Orlick M., Barnard N., Hait W.N., and Toppmeyer D.L. Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer. Breast J 9 2 (2003) 116-119
15. Shmueli E., Wigler N., and Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40 3 (2004) 379-382
16. Weitzen R., Zach L., Kaufman B., Tichler T., Rath P., Pfeffer R., Baram J., David M.B., Rizel S., and Catane R. High incidence of brain metastasis (BM) in patients on trastuzumab (H) for advanced breast cancer. Proc Am Soc Clin Oncol 21 (2002) Abstract
17. Pestalozzi B.C., and Brignoli S. Trastuzumab in CSF. J Clin Oncol 18 11 (2000) 2349-2351
18. Cox D.R. The analyses of binary data (1970), Methuen, London
19. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1959) 457-481
20. Trillet V., and Biron P. Brain metastases: diagnostic and therapeutic strategy. Presse Med 18 30 (1989) 1471-1475
21. Crivellari D., Pagani O., Veronesi A., Lombardi D., Nole F., Thurlimann B., Hess D., Borner M., Bauer J., Martinelli G., Graffeo R., Sessa C., and Goldhirsch A. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12 3 (2001) 353-356
22. Fuchs I.B., Loebbecke M., Buhler H., Stoltenburg-Didinger G., Heine B., Lichtenegger W., and Schaller G. HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol 20 19 (2002) 4130-4133
23. Pestalozzi B.C. Correction: meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol 19 20 (2001) 4091
24. Bergman I., Barmada M.A., Griffin J.A., and Slamon D.J. Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody. Clin Cancer Res 7 7 (2001) 2050-2056
25. Grossi P.M., Ochiai H., Archer G.E., McLendon R.E., Zalutsky M.R., Friedman A.H., Friedman H.S., Bigner D.D., and Sampson J.H. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 9 15 (2003) 5514-5520
26. Hernan R., Fasheh R., Calabrese C., Frank A.J., Maclean K.H., Allard D., Barraclough R., and Gilbertson R.J. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63 1 (2003) 140-148
27. Lower E.E., Drosick D.R., Blau R., Brennan L., Danneman W., and Hawley D.K. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 4 2 (2003) 114-119
28. Miller K.D., Weathers T., Haney L.G., Timmerman R., Dickler M., Shen J., and Sledge Jr. G.W. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14 7 (2003) 1072-1077